The FDA issued a black box warning for Ocaliva (obeticholic acid), a liver disease medication that was incorrectly dosed as daily instead of weekly for patients with primary biliary cholangitis (PBC), increasing the risk of serious liver injury and worsening liver problems.
Source: Drug Industry Daily